Raymond James & Associates Nektar Therapeutics Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	SELL	$3.04 - $5.14 $16,957 - $28,670	-5,578 Reduced 35.8%	10,001 $32,000
Q2 2022 Aug 12, 2022	SELL	$3.17 - $6.17 $7,671 - $14,931	-2,420 Reduced 13.45%	15,579 $59,000
Q1 2022 May 11, 2022	SELL	$4.16 - $13.72 $43,750 - $144,293	-10,517 Reduced 36.88%	17,999 $97,000
Q4 2021 Feb 08, 2022	SELL	$10.83 - $18.41 $33,139 - $56,334	-3,060 Reduced 9.69%	28,516 $385,000
Q3 2021 Nov 02, 2021	BUY	$13.07 - $18.84 $51,770 - $74,625	3,961 Added 14.34%	31,576 $567,000
Q2 2021 Aug 11, 2021	SELL	$16.52 - $20.4 $23,706 - $29,273	-1,435 Reduced 4.94%	27,615 $474,000
Q1 2021 May 14, 2021	BUY	$16.56 - $25.46 $37,508 - $57,666	2,265 Added 8.46%	29,050 $581,000
Q4 2020 Feb 12, 2021	BUY	$15.77 - $19.03 $1,892 - $2,283	120 Added 0.45%	26,785 $455,000
Q3 2020 Nov 04, 2020	SELL	$16.59 - $24.79 $6,669 - $9,965	-402 Reduced 1.49%	26,665 $442,000
Q2 2020 Jul 28, 2020	BUY	$16.86 - $23.44 $23,856 - $33,167	1,415 Added 5.52%	27,067 $627,000
Q1 2020 Apr 21, 2020	SELL	$14.47 - $27.96 $6,989 - $13,504	-483 Reduced 1.85%	25,652 $458,000
Q4 2019 Feb 12, 2020	BUY	$15.87 - $23.12 $25,439 - $37,061	1,603 Added 6.53%	26,135 $564,000
Q3 2019 Nov 07, 2019	SELL	$16.91 - $36.27 $602,959 - $1.29 Million	-35,657 Reduced 59.24%	24,532 $447,000
Q2 2019 Aug 06, 2019	BUY	$31.0 - $36.3 $535,370 - $626,901	17,270 Added 40.24%	60,189 $2.14 Million
Q1 2019 May 06, 2019	BUY	$31.58 - $46.35 $34,548 - $50,706	1,094 Added 2.62%	42,919 $1.44 Million
Q4 2018 Feb 11, 2019	SELL	$30.43 - $56.65 $489,405 - $911,101	-16,083 Reduced 27.77%	41,825 $1.38 Million
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $457,073 - $673,804	-9,838 Reduced 14.52%	57,908 $3.53 Million
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $1.13 Million - $2.55 Million	-24,402 Reduced 26.48%	67,746 $3.31 Million
Q1 2018 May 14, 2018	SELL	$57.4 - $108.44 $2.46 Million - $4.65 Million	-42,869 Reduced 31.75%	92,148 $9.79 Million
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $163,833 - $430,578	7,117 Added 5.56%	135,017 $8.06 Million
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $16,900 - $22,800	950 Added 0.75%	127,900 $3.07 Million
Q2 2017 Aug 14, 2017	BUY	N/A	126,950	126,950 $2.48 Million

Others Institutions Holding NKTR

# of Institutions

147

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$17 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$16.2 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$14 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$10.1 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$9.84 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account